Trial Outcomes & Findings for Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL) (NCT NCT04017754)
NCT ID: NCT04017754
Last Updated: 2021-07-30
Results Overview
Manose Binding Lectin level in a blood sample
COMPLETED
452 participants
At first consultation. Results accessible within 3 weeks.
2021-07-30
Participant Flow
The study sample consisted of 267 female patients with RPL fulfilling the inclusion criterias.
Participant milestones
| Measure |
Study Sample
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
Control Group 1
The MBL control group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Overall Study
STARTED
|
267
|
185
|
|
Overall Study
COMPLETED
|
267
|
185
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)
Baseline characteristics by cohort
| Measure |
Study Sample
n=267 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and a parental chromosomal analysis in most cases.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
267 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Age, Continuous
|
33.2 years
STANDARD_DEVIATION 5.3 • n=5 Participants
|
|
Sex: Female, Male
Female
|
267 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
267 participants
n=5 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
0 participants
n=5 Participants
|
|
Region of Enrollment
Denmark
|
267 participants
n=5 Participants
|
|
Body mass index
|
25.4 kg/m²
n=5 Participants
|
|
Number of consecutive pregnancy losses
|
3 consecutive pregnancy losses
n=5 Participants
|
|
Percentage with primary Recurrent pregnancy loss (RPL)
|
53.9 Percentage of all RPL patients
n=5 Participants
|
PRIMARY outcome
Timeframe: At first consultation. Results accessible within 3 weeks.Population: 18 women were pregnant \<12 weeks when blood sample was collected.
Manose Binding Lectin level in a blood sample
Outcome measures
| Measure |
Study Sample
n=267 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=185 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Plasma MBL Level (ug/ml)
|
717 ug/l
Interval 164.0 to 2131.0
|
1717 ug/l
Interval 505.0 to 3528.0
|
SECONDARY outcome
Timeframe: at deliveryPopulation: Patients who have given birth after admission within each p-MBL level subgroup
\<2500g
Outcome measures
| Measure |
Study Sample
n=76 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=21 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Participants Giving Birth After Recurrent Pregnancy Loss (RPL) to a Child With Low Birth Weight
|
3 participants
|
1 participants
|
SECONDARY outcome
Timeframe: At first consultationPopulation: participants who had sRPL; thus, who had given birth before admission to at least one child. Data concerns first delivery.
\<2500g
Outcome measures
| Measure |
Study Sample
n=51 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=25 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Participants Giving Birth Before RPL to a Child With Low Birth Weight
|
4 participants
|
2 participants
|
SECONDARY outcome
Timeframe: at delivery\<1500g
Outcome measures
| Measure |
Study Sample
n=76 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=21 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Participants Giving Birth After RPL to a Child With Very Low Birth Weight
|
0 participants
|
0 participants
|
SECONDARY outcome
Timeframe: At first consultation\<1500g
Outcome measures
| Measure |
Study Sample
n=51 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=25 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Participants Giving Birth Before RPL to a Child With Very Low Birth Weight
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Developed from 20 weeks gestation and until 6 weeks postpartum. Data collected at delivery.High blood pressure and proteinuria
Outcome measures
| Measure |
Study Sample
n=79 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Participants With Preclampsia in Pregnancy After RPL
|
7 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Developed from 20 weeks gestation and until 6 weeks postpartum. Data collected at first consultation.High blood pressure and proteinuria
Outcome measures
| Measure |
Study Sample
n=51 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=25 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Participants With Preclampsia in Pregnancy Before RPL
|
6 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: at deliveryA surgical delivery in women who were planned for vaginal delivery initially, but an acute indication for caesarean delivery has since developed.
Outcome measures
| Measure |
Study Sample
n=79 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=22 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Emergency Caesarean Section After RPL
|
10 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: At first consultationA surgical delivery in women who were planned for vaginal delivery initially, but an acute indication for caesarean delivery has since developed
Outcome measures
| Measure |
Study Sample
n=53 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=24 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Emergency Caesarean Section Before RPL
|
12 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: at deliveryA surgical delivery in women who were planned for caesarean delivery
Outcome measures
| Measure |
Study Sample
n=79 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=22 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Elective Caesarean Section After RPL
|
13 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: At first consultationA surgical delivery in women who were planned for caesarean delivery
Outcome measures
| Measure |
Study Sample
n=53 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=24 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Elective Caesarean Section Before RPL
|
6 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: During deliveryHemorrhage of \>999 ml
Outcome measures
| Measure |
Study Sample
n=78 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Severe Peripartum Hemorrhage in Birth After RPL
|
6 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: At first consultationHemorrhage of \>999 ml in minimum one previous birth befor RPL
Outcome measures
| Measure |
Study Sample
n=45 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=21 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Severe Peripartum Hemorrhage in Birth Before RPL
|
8 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: During deliveryHemorrhage of 500-1000 ml
Outcome measures
| Measure |
Study Sample
n=78 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Moderate Peripartum Hemorrhage in Birth After RPL
|
21 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: At first consultationHemorrhage of 500-1000 ml in minumum one previous birth before RPL
Outcome measures
| Measure |
Study Sample
n=45 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=21 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With Moderate Peripartum Hemorrhage in Birth Before RPL
|
6 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: at delivery\<37 weeks of gestation
Outcome measures
| Measure |
Study Sample
n=78 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=22 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Preterm Birth in Birth After RPL
|
8 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: At first consultation\<37 weeks of gestation
Outcome measures
| Measure |
Study Sample
n=49 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Preterm Birth in Birth Before RPL
|
4 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: at delivery\<32 weeks of gestation
Outcome measures
| Measure |
Study Sample
n=78 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=21 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Very Preterm Birth in Birth After RPL
|
2 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: At first consultation\<32 weeks of gestation
Outcome measures
| Measure |
Study Sample
n=49 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Very Preterm Birth in Birth Before RPL
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: At deliveryPopulation: male:female ratio
Gender ratio in births before RPL
Outcome measures
| Measure |
Study Sample
n=79 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Gender Ratio of Children Born After RPL
|
1.08 male:female ratio
|
2.29 male:female ratio
|
SECONDARY outcome
Timeframe: At first consultationGender ratio in births after RPL
Outcome measures
| Measure |
Study Sample
n=47 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Gender Ratio of Children Born Before RPL
|
3.27 male:female ratio
|
1.88 male:female ratio
|
SECONDARY outcome
Timeframe: 1 week after deliveryStillbirth are defined as fetal death \>22 weeks of gestation and within 1 week after delivery
Outcome measures
| Measure |
Study Sample
n=79 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=23 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Stillbirth After RPL
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: At first consultationStillbirth are defined as fetal death \>22 weeks of gestation and within 1 week after delivery - all women with min one previous birth are included in this analysis.
Outcome measures
| Measure |
Study Sample
n=54 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=26 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Stillbirth Before RPL
|
4 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: Follow up at study end.Number of women who give birth to a healthy liveborn child after RPL
Outcome measures
| Measure |
Study Sample
n=119 Participants
Women with unexplained recurrent pregnancy loss. Only patients with a history of 3 or more consecutive spontaneous pregnancy losses were included. Both biochemical and clinical losses documented in hospital records were accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social and genetic reasons were not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
At the first consultation in The Centre for Recurrent Pregnancy Loss of Western Denmark, all women have a diagnostic work-up, including collection of an obstetric and gynaecologic history, a routine blood analysis, a uterine hydrosonography, hysteroscopy, or hysterosalpingography, and additionally a parental chromosomal analysis in most cases.
|
MBL Reference Group
n=46 Participants
The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information than their plasma MBL level. After informed approval, all controls had an extra blood sample taken, which was analysed for MBL.
|
|---|---|---|
|
Patients With a Liveborn After RPL
|
79 Participants
|
23 Participants
|
Adverse Events
Study Sample
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Caroline Nørgaard-Pedersen
Aalborg University Hospital, Gynecologic and Obstetric department
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place